Analyst Price Targets — RGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 1:03 pm | — | Canaccord Genuity | $145.00 | $132.19 | TheFly | Repligen price target lowered to $145 from $165 at Canaccord |
| April 17, 2026 8:48 am | — | Redburn Partners | $160.00 | $127.09 | TheFly | Repligen initiated with a Buy at Rothschild & Co Redburn |
| April 14, 2026 10:43 am | Luke Sergott | Barclays | $145.00 | $122.59 | TheFly | Repligen price target lowered to $145 from $175 at Barclays |
| January 16, 2026 12:18 pm | Dan Leonard | UBS | $200.00 | $161.69 | TheFly | Repligen price target raised to $200 from $190 at UBS |
| December 15, 2025 11:29 am | — | Wells Fargo | $190.00 | $157.33 | TheFly | Repligen price target raised to $190 from $175 at Wells Fargo |
| December 15, 2025 10:56 am | — | Barclays | $200.00 | $157.33 | TheFly | Repligen price target raised to $200 from $175 at Barclays |
| October 29, 2025 10:58 am | — | Canaccord Genuity | $165.00 | $151.57 | TheFly | Repligen price target raised to $165 from $150 at Canaccord |
| October 29, 2025 9:35 am | — | Barclays | $175.00 | $151.57 | TheFly | Repligen price target raised to $175 from $160 at Barclays |
| October 28, 2025 5:41 pm | Matthew Stanton | Jefferies | $160.00 | $154.24 | StreetInsider | Repligen (RGEN) PT Raised to $160 at Jefferies |
| October 2, 2025 10:44 am | Luke Sergott | Barclays | $160.00 | $145.81 | TheFly | Repligen price target raised to $160 from $150 at Barclays |
Latest News for RGEN
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built…
Massachusetts Financial Services Co. MA acquired a new position in Repligen Corporation (NASDAQ: RGEN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,215,527 shares of the biotechnology company's stock, valued at approximately $199,176,000. Massachusetts Financial Services Co. MA
Azzad Asset Management Inc. ADV cut its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 59.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,314 shares of the biotechnology company's stock after selling 4,869 shares during the quarter. Azzad Asset
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ: RGEN) by 241.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 746,306 shares of the biotechnology company's stock after buying an additional 527,714 shares during
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RGEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.